Early study shows Ebola vaccine to be safe
the ONA take:
The Ad5-EBOV Ebola virus vaccine was proven safe in an early study in healthy adults in China, a new study published in the journal The Lancet has shown.
The Phase 1 study evaluated the safety of the vaccine in 120 healthy people in China's Jiangsu province. Participants received either a low dose or high dose of the vaccine, or placebo.
Participants were then monitored for over 28 days for any adverse events and an immune response. Results showed that no serious adverse events occurred and antibodies were significantly increased in participants.
Although the study did not demonstrate whether the immune response lasted longer than 28 days or whether a booster immunization would be needed, researchers say that the vaccine has potential.
Ad5-EBOV is not the only vaccination being studied to combat the Ebola virus, which has killed more 10,000 people since the beginning of 2014.
Other vaccines are currently in Phase III testing where they are being used in people at risk of infection in west Africa. The United Nations Ebola response team said this week that the Ebola outbreak should be gone by this summer.
The Ad5-EBOV Ebola virus vaccine was proven safe in an early study in healthy adults in China.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|